Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
small molecule alpha7beta1 integrin activators
- Development stage
- Preclinical
- Lead developer
- Sarcomatrix Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Small molecule α7β1 integrin activators are a therapeutic program developed by Sarcomatrix Therapeutics, targeting various forms of muscular dystrophy. The α7β1 integrin is a major laminin receptor in skeletal muscle that plays a critical role in maintaining the structural integrity of the sarcolemma. By utilizing small molecules to increase the expression or functional activity of this integrin complex, the therapy aims to compensate for the loss of dystrophin or other structural proteins, thereby stabilizing muscle fibers and promoting regeneration. The lead candidate in this program is S-969, and the company has also explored the repurposing of sunitinib for this mechanism. The program is currently in preclinical development for indications including Duchenne, Becker, and Limb-Girdle muscular dystrophies.
- Other names
- alpha7beta1 integrin activatorsalpha-7beta1 integrin activatorsalpha 7beta1 integrin activators
02
Targets
MST/LATS (Hippo signaling pathway kinases)Cyclin-dependent kinase 2 / Cyclin-dependent kinase 4 / Cyclin-dependent kinase 5α7β1 (Integrin α7β1)SPAK/OSR1 (Ste20-related proline-alanine-rich kinase (SPAK) and Oxidative stress-responsive kinase 1 (OSR1))
Beyond the preview
Go deeper on small molecule alpha7beta1 integrin activators.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on small molecule alpha7beta1 integrin activators.